Arcus Biosciences (RCUS) Stock Forecast & Price Target

Arcus Biosciences is favorably positioned because casdatifan is advancing in a pivotal PEAK-1 program and a broad ARC-20 dataset, with the company aiming to validate a differentiated HIF-2α profile in clear cell renal cell carcinoma. The cited analysis argues that a ~15.5-month pooled median PFS would already be competitive, while higher readouts could strengthen differentiation, support rapid adoption of the cabozantinib combination, and help underpin an estimated $3.2B peak worldwide revenue opportunity in ccRCC. Beyond casdatifan, quemliclustat in PRISM-1, expected data in 1H:27, and emerging immunology assets entering the clinic in 3Q:26 and 1H:27 broaden the pipeline and reduce dependence on a single program.

Arcus Biosciences is viewed negatively because its valuation depends heavily on late-stage clinical success, yet domvanalimab and AB154 still face meaningful efficacy, safety, and regulatory uncertainty, with any setback likely undermining both development and future sales estimates. The investment case also looks vulnerable to competitive pressure from current and emerging therapies, since the company’s own framework shows that differentiation versus belzutifan-plus-lenvatinib remains unclear in key ARC-20 scenarios and that later-to-market positioning is a risk. Although Q2 showed a $91M net loss and $775M in cash and equivalents expected to fund operations until at least 2H:28, the ongoing cash burn and concentrated pipeline risk leave limited margin for error.